Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem
Year: 2017
Type: article
Source: Nature Reviews Drug Discovery
DOI: 10.1038/nrd.2017.153
Authors: Stephen P. Arnerić, Jesse M. Cedarbaum, Sean Khozin, Spyros Papapetropoulos, Derek L. Hill, Michael Ropacki, Jane Rhodes, Penny A. Dacks, Lynn D. Hudson, Mark Forrest Gordon, Volker D. Kern, Klaus Romero, George Vradenburg, Rhoda Au, Daniel R. Karlin, Maurizio F. Facheris, Cheryl J. Fitzer-Attas, Ottavio V. Vitolo, Jian Wang, Bradley M. Miller, Jeffrey A. Kaye
Institutions: Critical Path Institute, Biogen (United States), United States Food and Drug Administration, AbbVie (United States), Massachusetts General Hospital, Ixico (United Kingdom), Loma Linda University, Alzheimer's Drug Discovery Foundation, CHDI Foundation, Eli Lilly (United States), Boehringer Ingelheim (United States), UsAgainstAlzheimer, Boston University, Pfizer (United States), Oregon Health & Science University
Language: English
Subfield: General Health Professions
Field: Health Professions
Domain: Health Sciences
Open Access status: closed
Award: G1747133292
OpenAlex ID: W2759771684